The Receptor for Advanced Glycation Endproducts is a pattern recognition receptor that can be activated by advanced glycation endproducts, members of the S100 protein family or amyloid b (Ab) peptides. Ab oligomers are generated by proteolytic digestion of the amyloid precursor protein (APP) and are currently believed to be the most toxic forms of Ab. We recently showed that Ab oligomers interact preferentially with the V domain of RAGE whereas other forms of Ab (fibrils, aggregates) interact with other domains of the receptor. We showed that engagement of RAGE by Ab oligomers lead to neuronal apoptosis. Blocking the interaction of RAGE by Ab oligomers could lead to significant reduction of neuronal death in Alzheimer's patients. We propose to use single chain monoclonal antibody (light chain) to block RAGE/ Ab interaction. Single chain domain antibodies have been shown to cross the blood brain barrier and are thus promising agents to target and block brain receptors. We have recently generated a Fab fragment antibody phage display library targeting RAGE. Ten selected Fabs reacting with RAGE presented truncated and thus non- functional heavy chains. We could sub-cloned the light chain of truncated Fab B2 into a His tag containing vector and purified it to homogeneity. We showed that the recombinant light chain could bind to RAGE and displace RAGE ligand S100B in vitro. We propose here to further evaluate these single domain light chain antibodies by measuring their binding affinities to RAGE in vitro (ELISA) and on the surface of cells. We will then test the ability of these antibodies to block cell death triggered by the engagement of RAGE by distinct b amyloid oligomeric forms.

Public Health Relevance

The activation of the Receptor for Advanced Glycation Endproducts by amyloid b peptides plays an important role in Alzheimer's disease (AD). Single domain monoclonal antibodies cross the blood brain barrier and are promising agents to treat AD. We propose to use single domain light chain monoclonal antibodies to block RAGE mediated cell death in AD.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Small Research Grants (R03)
Project #
1R03AG040580-01
Application #
8175167
Study Section
Special Emphasis Panel (ZRG1-MDCN-C (56))
Program Officer
Refolo, Lorenzo
Project Start
2011-08-01
Project End
2013-07-31
Budget Start
2011-08-01
Budget End
2012-07-31
Support Year
1
Fiscal Year
2011
Total Cost
$58,835
Indirect Cost
Name
North Dakota State University
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
803882299
City
Fargo
State
ND
Country
United States
Zip Code
58108
Indurthi, Venkata S K; Leclerc, Estelle; Vetter, Stefan W (2012) Interaction between glycated serum albumin and AGE-receptors depends on structural changes and the glycation reagent. Arch Biochem Biophys 528:185-96